Pfizer Inc. $PFE Shares Acquired by Wealth Alliance LLC

Wealth Alliance LLC boosted its position in Pfizer Inc. (NYSE:PFE) by 40.5% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 91,345 shares of the biopharmaceutical company’s stock after buying an additional 26,318 shares during the period. Wealth Alliance LLC’s holdings in Pfizer were worth $2,327,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Fiduciary Alliance LLC increased its stake in Pfizer by 46.4% during the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock valued at $3,701,000 after buying an additional 46,043 shares during the period. Y Intercept Hong Kong Ltd bought a new position in shares of Pfizer in the third quarter valued at approximately $3,019,000. Vista Investment Partners LLC increased its stake in shares of Pfizer by 236.1% during the third quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock valued at $1,774,000 after acquiring an additional 48,900 shares during the period. Money Concepts Capital Corp increased its position in shares of Pfizer by 29.9% during the 3rd quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock valued at $6,325,000 after purchasing an additional 57,188 shares during the period. Finally, Generali Investments CEE investicni spolecnost a.s. raised its position in Pfizer by 76.4% in the third quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock worth $2,784,000 after acquiring an additional 47,319 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently commented on PFE. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Citigroup assumed coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price objective on the stock. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research note on Wednesday, February 4th. Zacks Research lowered shares of Pfizer from a “hold” rating to a “strong sell” rating in a research report on Monday, January 26th. Finally, Barclays initiated coverage on shares of Pfizer in a research note on Thursday. They issued an “underweight” rating and a $25.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $27.84.

Pfizer Stock Performance

NYSE PFE traded down $0.27 during midday trading on Friday, hitting $26.59. The company had a trading volume of 3,287,500 shares, compared to its average volume of 49,086,516. The firm has a fifty day simple moving average of $25.94 and a two-hundred day simple moving average of $25.29. The stock has a market cap of $151.18 billion, a price-to-earnings ratio of 19.49 and a beta of 0.47. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The firm’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period last year, the business earned $0.63 earnings per share. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.5%. Pfizer’s dividend payout ratio is currently 126.47%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.